Circulating Tumor Cells Could Lead To Relapse And Early Death

Circulating tumor cells could mean relapse and early death for breast cancer patients, researchers say. Hence targeting such cells could be a good strategy, they believe.

Scientists with the University of Texas MD Anderson Cancer Center in Houston presented a poster session on the issue at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium on Friday.

They also said that patients with higher percentages of epithelial cells, or the presence of a specific cellular transition, had higher chances for relapse.

“Building on the information from this study, we eventually may be able to use these molecular markers to identify breast cancer patients with a high likelihood of developing metastasis or relapsing. This may allow physicians to design specific treatments to help patients achieve better outcomes,” said James M. Reuben, Ph.D., professor in MD Anderson’s Department of Hematopathology, and co-corresponding author of the study.

Stem cells have common receptor

High-dose chemotherapy followed by autologous hematopoietic peripheral blood stem cell transplantation (ASCT) offers modest complete response rates for some patients with metastatic breast cancer. However, tumor cells that spread to the bone may be recruited and mobilized along with hematopoietic stem cells to increase a patient’s chance of relapse.

“We hypothesized that since the breast tumor cells have the same CXRX4 receptor as hematopoietic stem cells, we might mobilize or recruit tumor cells by using a growth factor proven to mobilize blood stem cells,” Reuben said.

New Approach to Fight Infection Via Stem-cell Therapy
A commonly used type of bone marrow stem cell may be able to help treat sepsis, a deadly condition that can occur when an infection spreads throughout the body, says a new study

Epithelial-to-mesenchymal transition (EMT) is recognized as an important part of metastasis. Epithelial cells line the organs and cavities of the body and usually are not mobile. Mesenchymal cells are mobile and can differentiate into many cell types, for example, to repair injury. EMT has been shown to repress E-cadherin, decrease cell-cell adhesion and increase a cell’s capacity to move. An estimated 80 percent of solid tumors are cancers of the epithelial tissue.

Blood examined for epithelial cells, CTC

Aphaeresis was used to harvest blood stem cells from 21 metastatic breast cancer patients before transplantation. To determine levels of CTCs, blood samples were collected before aphaeresis (baseline) and one month after transplantation.

“We used the flow cytometry method of staining for both epithelial and stem cell markers,” said Hui Gao, Ph.D., a research scientist in MD Anderson’s Department of Hematopathology and co-first author of the study. “Then we enumerated the percentages of epithelial cells and cancer stem cells to see how these correlated with patient survival.”

Cells, survival correlated

The median time to follow-up after transplant was 16.4 months. At follow-up, eight women were cancer free, and 13 had relapsed. The median time to relapse was nine months, and median survival was 14.4 months.

CTCs were found in six patients before and in nine patients after transplant. Patients with more than five CTCs before transplant had shorter overall survival. If five or more CTCs were found after transplant, both relapse-free and overall survival times were shorter.

Patients with percentages of CD326+ epithelial cells above the median had shorter relapse-free survival times,10 months versus 23 months. Also, patients with CTCs with mesenchymal features had a shorter relapse-free survival, seven months, compared to those who had CTCs without such features, 23 months.

Next steps

The researchers hope to carry the research forward into a prospective study in the near future.

“If we really can target CTCs with mesenchymal features, we may be able to control disease much more efficiently,” said Naoto T. Ueno, M.D., Ph.D., professor in MD Anderson’s Departments of Breast Medical Oncology and Stem Cell Transplantation and Cellular Therapy, and co-corresponding author of the study.

The research was funded by grants from The University of Texas Health Science Center, the National Cancer Institute, the State of Texas Rare and Aggressive Breast Cancer Research Program and an American Airlines Susan G. Komen Promise Grant.

Source-Medindia